Biofourmis, which combines AI-based data analytics and biosensors to monitor the progress of medical treatments, has raised funding from one of the world’s most high-profile investors. The digital therapeutics company, which launched in Singapore and is now headquartered in Boston, announced today it closed a $100 million Series C led by SoftBank Vision Fund 2, with participation from returning investors Openspace Ventures, MassMutual Ventures, Sequoia Capital and EDBI. The company’s last funding announcement was in May 2019 for a $35 million Series A led by Sequoia India and MassMutual, the venture capital arm of Massachusetts Mutual Life Insurance Company.